Dapagliflozin on Blood Pressure Variability and Ambulatory Arterial Stiffness Index in Hypertension
Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
The prevalence of arterial hypertension has remained the same in the last 5 years, however,
almost 50% of the population continues without an adequate adjustment according to the
National Health Survey of the Midway 2016.
It has been shown that the variability of blood pressure (VBP) during 24 h and visit-visit is
associated with cardiovascular diseases (CVD) over the effect of blood pressure (BP) itself.
On the other hand, arterial stiffness is well known as an independent factor of CVD risk and
for its evaluation the ambulatory arterial stiffness index (AASI) has been proposed. AASI and
the VPA obtained through an evaluation by ambulatory BP monitoring (ABPM) individual of 24 h.
Dapagliflozin is an inhibitor of the sodium-glucose cotransporter type 2 (iSGLT2) for the
treatment of diabetes mellitus type 2 (DM2) that promotes natriuresis and osmotic diuresis,
which produces a decrease in plasma volume and a decrease in BP.
The aim of ths study is to evaluate the effect of dapagliflozin on VBP and AASI in
individuals with stage I hypertension whitout DM2.
The investigators hypothesis is that the administration of dapagliflozin decreases the VBP
and AASI in individuals with stage I hypertension whitout DM2.